NASDAQ:MGTX

MeiraGTx Stock Forecast, Price & News

$14.31
+0.61 (+4.45 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.64
Now: $14.31
$14.54
50-Day Range
$13.08
MA: $14.96
$17.80
52-Week Range
$11.35
Now: $14.31
$18.45
Volume90,623 shs
Average Volume113,717 shs
Market Capitalization$633.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.
MeiraGTx logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTX
CUSIPN/A
CIKN/A
Phone646-860-7985
Employees219
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.29 million
Book Value$5.22 per share

Profitability

Net Income$-54,750,000.00
Net Margins-283.20%

Miscellaneous

Market Cap$633.42 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

MeiraGTx (NASDAQ:MGTX) Shares Gap Up to $14.15
March 26, 2021 |  americanbankingnews.com
MeiraGTx (NASDAQ:MGTX) Shares Gap Down to $15.93
March 24, 2021 |  americanbankingnews.com
Our First Look At MeiraGTx Holdings - Seeking Alpha
January 27, 2021 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.45 out of 5 stars

Medical Sector

586th out of 2,021 stocks

Biological Products, Except Diagnostic Industry

83rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$14.31
+0.61 (+4.45 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

Is MeiraGTx a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MeiraGTx stock.
View analyst ratings for MeiraGTx
or view top-rated stocks.

What stocks does MarketBeat like better than MeiraGTx?

Wall Street analysts have given MeiraGTx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MeiraGTx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for MeiraGTx
.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) issued its quarterly earnings data on Thursday, March, 11th. The company reported ($0.25) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.05. The business earned $3.79 million during the quarter, compared to analyst estimates of $3.20 million. MeiraGTx had a negative trailing twelve-month return on equity of 29.14% and a negative net margin of 283.20%.
View MeiraGTx's earnings history
.

How has MeiraGTx's stock price been impacted by COVID-19 (Coronavirus)?

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MGTX shares have increased by 1.5% and is now trading at $14.31.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MGTX?

4 brokers have issued 12-month target prices for MeiraGTx's stock. Their forecasts range from $20.00 to $45.00. On average, they expect MeiraGTx's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 130.6% from the stock's current price.
View analysts' price targets for MeiraGTx
or view top-rated stocks among Wall Street analysts.

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the following people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 56, Pay $8.48M)
  • Mr. Richard Brian Giroux B.A., COO & CFO (Age 47, Pay $7.47M)
  • Mr. Robert Wollin J.D., Gen. Counsel & Sec.
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer (Age 58)
  • Dr. Michel Michaelides M.D., Head of Clinical Ophthalmology
  • Ms. Christine Elise Sheehy, Sr. VP of Global Integration (Age 53)
  • Mr. Joel P. Brooks, Sr. VP of Fin. (Age 62)
  • Mr. Tim Randall, Sr. VP of Risk & Internal Controls
  • Dr. Alastair Leighton, Sr. VP of Manufacturing & Supply Chain
  • Dr. Robert K. Zeldin M.D., Chief Medical Officer (Age 58)

Who are some of MeiraGTx's key competitors?

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

When did MeiraGTx IPO?

(MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $14.31.

How much money does MeiraGTx make?

MeiraGTx has a market capitalization of $633.42 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does MeiraGTx have?

MeiraGTx employs 219 workers across the globe.

What is MeiraGTx's official website?

The official website for MeiraGTx is www.meiragtx.com.

Where are MeiraGTx's headquarters?

MeiraGTx is headquartered at 450 East 29thStreet 14thFloor, NEW YORK NY, 10016.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.